Head-To-Head Analysis: Sagent Pharmaceuticals (NASDAQ:SGNT) versus Innocoll Holdings PLC (INNL)

Sagent Pharmaceuticals (NASDAQ: SGNT) and Innocoll Holdings PLC (NASDAQ:INNL) are both pharmaceuticals – nec companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Insider and Institutional Ownership

34.2% of Innocoll Holdings PLC shares are owned by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Sagent Pharmaceuticals and Innocoll Holdings PLC, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sagent Pharmaceuticals 0 0 0 0 N/A
Innocoll Holdings PLC 0 3 1 0 2.25

Innocoll Holdings PLC has a consensus price target of $4.50, suggesting a potential upside of 91.49%. Given Innocoll Holdings PLC’s higher possible upside, analysts plainly believe Innocoll Holdings PLC is more favorable than Sagent Pharmaceuticals.

Valuation & Earnings

This table compares Sagent Pharmaceuticals and Innocoll Holdings PLC’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Sagent Pharmaceuticals N/A N/A N/A ($0.77) -28.26
Innocoll Holdings PLC N/A N/A N/A ($1.66) -1.42

Sagent Pharmaceuticals is trading at a lower price-to-earnings ratio than Innocoll Holdings PLC, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Sagent Pharmaceuticals and Innocoll Holdings PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sagent Pharmaceuticals -0.72% -0.81% -0.59%
Innocoll Holdings PLC -1,051.20% N/A -138.53%

Summary

Innocoll Holdings PLC beats Sagent Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Sagent Pharmaceuticals Company Profile

Sagent Pharmaceuticals, Inc. is a specialty and generic pharmaceutical company. The Company is a provider of pharmaceuticals to the hospital market, which it sells primarily throughout North America. It is focused on developing, manufacturing, sourcing and marketing injectable pharmaceutical products to the hospital market. It operates through two segments: Sagent US, consisting of the Company’s operations in the United States and the Sagent (China) Pharmaceuticals Co. Ltd. (SCP) manufacturing facility, and Omega, which is focused on the Canadian and international markets. It offers a range of products across anti-infective, oncology and critical care indications in a range of presentations, including single and multi-dose vials, pre-filled ready-to-use syringes and premix bags. Its Sagent US product portfolio includes approximately 60 marketed products that it offers in over 180 presentations, and its Omega segment offers over 50 products.

Innocoll Holdings PLC Company Profile

Innocoll Holdings Public Limited Company is a commercial-stage specialty pharmaceutical and medical device company with late-stage development programs. The Company operates through the segment of manufacture and sale of collagen-based pharmaceutical products. It utilizes collagen-based technology platform to develop its biodegradable and bioresorbable products and product candidates, which can be broken down by the body without the need for surgical removal or applied topically. Using its processes at its manufacturing facility, it derives and purifies bovine and equine collagen and then utilizes its technology platform to incorporate the purified collagen into its topical and implantable products. Its lead product candidates are XaraColl for the treatment of post-operative pain and Cogenzia for the treatment of diabetic foot infections. Its marketed products include CollaGUARD, Collatamp, Septocoll and RegenePro. It has initiated its Phase III efficacy trials for Cogenzia.

Receive News & Ratings for Sagent Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagent Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply